Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy

Benedikt Schworm
Ludwig Maximilians University Munich Faculty of Medicine: Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat

Nikolaus Luft
Ludwig Maximilians University Munich Faculty of Medicine: Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat

Leonie F Keidel
Ludwig-Maximilians-Universität München Medizinische Fakultät: Ludwig-Maximilians-Universität Munchen Medizinische Fakultät

Thomas C Kreutzer
Ludwig Maximilians University Munich Faculty of Medicine: Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat

Tina R Herold
Ludwig Maximilians University Munich Faculty of Medicine: Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat

Siegfried G Priglinger
Ludwig Maximilians University Munich Faculty of Medicine: Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat

Jakob Siedlecki (jakob.siedlecki@med.uni-muenchen.de)
Ludwig-Maximilians-Universität München, Department of Ophthalmology  https://orcid.org/0000-0002-0279-4823

Research article

Keywords: pachychoroid, pachychoroid neovasculopathy, central serous chorioretinopathy, choroidal neovascularization, optical coherence tomography, vascular endothelial growth factor, ranibizumab

DOI: https://doi.org/10.21203/rs.3.rs-480574/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

To investigate the diagnostic value of choroidal thickness in the definition of pachychoroid neovasculopathy (PNV), especially in eyes treated with anti-vascular endothelial growth factor (VEGF) therapy.

Methods

Twenty-two consecutive eyes of 11 patients with uni- or bilateral PNV were analyzed. Anti-VEGF treatment was correlated with changes in choroidal thickness on enhanced depth imaging optical coherence tomography.

Results

There were 14 eyes with PNV and 8 non-neovascular partner eyes. Mean age was 64.2 ± 4.0 (range: 60–72), total follow-up was 1.8 ± 0.4 (1–2) years. In PNV eyes, choroidal thickness at baseline was 400 ± 58 (269–485) µm. After two years and 13 anti-VEGF injections on average, a mean reduction of -39 ± 10 (-26 to -56) % to final 241 ± 52 (162–327) µm was observed (p < 0.0001). Meanwhile, choroidal thickness in the partner eyes remained stable (p > 0.13 for all comparisons). A significant correlation of choroidal thinning and anti-VEGF injection rate was observed at year one (r=-0.79 ; R² = 0.63 ; p = 0.00073) and two (r=-0.69; R² = 0.48 ; p = 0.019). While 85.7 % of PNV eyes exceeded a pachychoroid threshold of ≥ 350 µm at baseline, this figure dropped to 21.4 % at year one and 0 % at year two.

Conclusion

In PNV, choroidal thickness significantly decreases with anti-VEGF therapy, resembling a “vanishing pachy-choroid”, and thus does not represent a valid long-term diagnostic criterium, especially when differentiating PNV from nAMD.

Key Messages

What was known: Pachychoroid neovasculopathy (PNV) is characterized by choroidal neovascularization above a thick choroid. What is new: In PNV, choroidal thickness decreases with increasing amounts of anti-VEGF injections. Thus, choroidal thickness becomes an unreliable diagnostic criterium in pre-treated eyes when differentiating PNV from neovascular AMD.

Background

Pachychoroid disorders of the macula are frequently complicated by a choroidal neovascularization (CNV)\(^1-3\). These include central serous chorioretinopathy (CSC), which can develop secondary CNV in up
to 25 % of cases\textsuperscript{1,3}, and \textit{pachychoroid neovasculopathy} (PNV), which represents CNV atop areas of thickened choroid without prior evidence of CSC\textsuperscript{4}.

Recently, Hwang et al.\textsuperscript{5} described a significant overlap of multimodal imaging findings in PNV and CSC complicated by CNV, and suggested that both might be variants of the same disease. Simultaneously, we have recently suggested the use of the term \textit{PNV} as a general term for both PNV and CSC complicated by CNV to facilitate the distinction of neovascular pachychoroid disorders from non-neovascular (CSC, pachychoroid pigment epitheliopathy (PPE)) and neovascular pachychoroid disease with an aneurysmal phenotype (polypoidal choroidal vasculopathy/or aneurysmal type 1 CNV)\textsuperscript{6}.

Due to the high amount of cumulative damage required for CNV formation in pachychoroid disease, patients with PNV are usually older than patients with pachychoroid pigment epitheliopathy (PPE) or acute CSC\textsuperscript{2}. Resultingly, PNV is often mistaken as, sometimes unresponsive, neovascular age-related macular degeneration (nAMD)\textsuperscript{7}, which can be aggravated by the CNV-induced disruption of retinochoroidal tissue, especially if the CNV is mimicking drusenoid pigment epithelium detachments\textsuperscript{8}.

Although both nAMD and PNV react well to anti-vascular growth factor (VEGF) therapy\textsuperscript{9-11}, a thorough discrimination between both entities is essential for further research endeavors targeting the very different underlying etiopathologies beyond anti-VEGF (drusen accumulation with age-related choroidal thinning vs. choroidal thickening and Haller vein dilation).

Based on the definition of pachychoroid disease, the presence of a thick choroid should be a prerequisite for its diagnosis\textsuperscript{2}. On the other hand, choroidal thickness is known to decrease with age\textsuperscript{12,13}, and moreover, might be influenced by disease duration, complications such as CNV and resulting disease-modifying intravitreal anti-VEGF therapy\textsuperscript{14,15}. The following study was therefore designed\textsuperscript{16} to investigate the validity of choroidal thickness in the definition of late-stage neovascular non-aneurysmatic pachychoroid disease, and its ability to discriminate between pachychoroid disease and nAMD.

**Methods**

**Participants**

For this retrospective cohort study, all eyes presenting with treatment-naïve CNV at the Ludwig Maximilians-University Munich, Germany, between January 2017 and May 2019 were screened for cases of PNV eligible for inclusion in this study, defined as: (i) Presence of a pachychoroid, defined as a) a subfoveal choroidal thickness $\geq 350\ \mu\text{m}$, or $\geq 250\ \mu\text{m}$ with a previous pre-documented history of CSC, b) with the presence of pachyvessels, defined as dilated lumina of the Haller’s layer and c) an attenuation of the overlying choroidal structures; (ii) Presence of a CNV; (iii) absence of CNV aneurysms/polyps; (iv) anti-VEGF therapy with a follow-up of $\geq 1$ year; (v) absence of classic drusen or reticular pseudodrusen on either eye; (vi) absence of anti-mineralocorticoid or photodynamic therapy during follow-up; (vii) absence of confounding comorbidities (diabetic retinopathy, hereditary retinal disease, diseases of the
vitreoretinal interface, status after vitrectomy, optic media opacification impeding sufficient image quality). Unaffected partner eyes were included as a control group. Institutional review board approval was obtained for this retrospective chart review, and the study adhered to the tenets of the Declaration of Helsinki. At the moment of data analysis, ethic’s committee approval was not required for retrospective, non-interventional studies.

Epidemiological data was obtained from each patient, including age, gender, previous ocular comorbidities and procedures, date of first diagnosis of PNV, date of first anti-VEGF injection, number of anti-VEGF injections, and objective refraction-based Snellen chart visual acuity at baseline and at years 1 and 2, which was later converted to logMAR for analysis.

**Multimodal imaging**

Multimodal imaging (all on Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany) was performed after pupil dilation with topical tropicamide 1% and phenylephrine 2.5 %. It included enhanced depth (EDI) spectral domain optical coherence tomography (SD-OCT) and near-infrared (NIR) confocal laser scanning ophthalmoscopy (CSLO) in every eye at each visit. OCT angiography was performed in every eye at baseline. Blue-autofluorescence (BAF) CSLO, fluorescein (FA) and/or indocyanine green (ICG) angiography and additional OCT angiography scans were performed at the investigator’s discretion.

**Measurement of choroidal thickness**

Choroidal measurements were obtained using the Heidelberg Eye Explorer (Heidelberg Engineering, Heidelberg, Germany) on enhance depth imaging OCT images in the 1:1 µm setting by two readers (JS, LK). In the case of disagreement, defined as a difference of > 10 µm\textsuperscript{17,18}, a third senior reader was consulted (BS). Sub-foveal choroidal thickness (SFCT) was measured directly underneath the fovea from the outer portion of the retinal pigment epithelium to the sclerochoroidal interface. Two further choroidal thickness measurements were obtained in analogous fashion in a distance of 1500 µm nasally and temporally of the fovea.

**Anti-VEGF treatment**

Treatment was primarily performed using a treat & extend regimen as described previously\textsuperscript{19,20}. In brief, each newly diagnosed CNV lesion was treated with an upload of three monthly injections of Ranibizumab (Novartis Pharma AG, Basel, Switzerland), after which the interval was extended or shortened by two weeks based on the absence or presence of new CNV activity. CNV activity was defined on OCT as (I) any new macular fluid, including SRF, (II) pigment epithelium detachment (PED) increasing central macular thickness > 50 µm, (III) new or increasing macular hemorrhage, or (IV) a decrease in visual acuity ≥ 1 Snellen chart line. Minimum and maximum interval between injections were 4 and 12 weeks, respectively. In the case of CNV reactivation, treatment was again started as in a newly diagnosed lesion. When patients did not consent with a treat & extend regimen, a pro-re-nata regimen was performed, using the same reactivation criteria as mentioned above.

**Statistical Analysis**
All data were gathered and analyzed in Microsoft Excel spreadsheets (Version 16.23 for Mac; Microsoft, Redmond, WA, USA). Statistical analysis was performed in SPSS Statistics 25 (IBM Germany GmbH, Ehningen, Germany). The level to indicate statistical significance was defined as p < 0.05. The Shapiro-Wilk and Kolmogorov-Smirnov tests were employed to test for normal distribution. Statistical analyses of intra-group differences were performed using the dependent two-tailed Student t-test and the Wilcoxon signed rank test. A repeated measures ANOVA test was used to compensate for multiple testing, if applicable. Pearson's correlation coefficient was used to test associations of dependent and independent variables.

Results

Baseline demographics

Twenty-two eyes of 11 patients were included in the analysis. Detailed baseline parameters of the study cohort can be found in Table 1. In brief, 14 (63.6 %) out of the 22 eyes had a diagnosis of PNV, and 8 eyes (36.4 %) were partner eyes without signs of neovascularization. Mean age was 64.2 ± 4.0 (range: 60–72) years with a female to male ratio of 4 / 7 (36.4 / 63.6 %). Total follow-up was 1.8 ± 0.4 (1–2) years. All eyes were available for the one-year analysis, and 77.2 % were available at year two. In total, 10 of the 22 eyes (45.5 %) had a history of CSC. In the anti-VEGF treatment group, these were 9 out of 14 eyes (64.3 %). In the control group, one eye out of 8 had a history of CSC (12.5 %), while 4 had PPE (50 %).

Macular morphology

At baseline, all eyes (100 %) diagnosed with PNV had subretinal fluid and a flat, irregular PED forming a double-layer sign. The presence of a type 1 CNV within the flat PED was confirmed on OCT angiography in all eyes (100 %). No eye showed intraretinal fluid or a type 2 CNV configuration at baseline.

In the 8 partner eyes, no case of flat irregular PED, CNV or intraretinal fluid was observed. Five eyes (62.5 %) showed characteristics of the non-neovascular spectrum of pachychoroid disorders. In 4 (50.0 %), pachychoroid pigment epitheliopathy (PPE) was found, while one eye (12.5 %) displayed CSC with subretinal fluid at baseline, which resolved without treatment after 9 weeks of follow-up.

Anti-VEGF treatment

In the first year, mean 7.0 ± 2.9 (2–11) injections were given. Due to disease inactivation after two injections, one patient expressed the wish to stop treatment on one eye (7.1 %). All other patients received an upload of Ranibizumab (92.9 %), after which three (23.1 %) asked for a continuation of treatment using a pro-re-nata regimen. In the remaining 10 patients, a treat & extend regimen with mean 8.5 ± 1.6 (8–11) injections was performed. In the second year, 11 out of the 14 PNV eyes (78.6 %) were treated with a mean of 6.5 ± 3.1 (1–10) injections. In these 11 eyes, a treat & extend regimen was used in 9 (81.8 %), and a pro-re-nata regimen in 2 eyes (18.2 %).

Subfoveal, nasal and temporal choroidal thickness
Choroidal thickness during follow-up is presented in detail in Fig. 1 and Table 2. In PNV eyes, mean SFCT at baseline was 400 ± 58 (269–485) µm. At year one, it significantly decreased to 295 ± 53 (210–393) µm (-25%; p < 0.0001). In year two, SFCT further decreased to 241 ± 52 (162–327) µm, resulting in an additional 20% reduction (p = 0.0003). Comparing baseline to end of follow-up at year two, a mean reduction of -39 ± 10 (-26 to -56)% occurred. Mean nasal choroidal thickness (CT) at baseline was 312 ± 42 (243–368) µm. At year one, a decrease to 249 ± 47 (180–332) was observed (-19%; p < 0.0018). In year two, nasal CT further decreased to 222 ± 40 (178–315) µm, resulting in an additional 12% reduction (p = 0.017). Comparing baseline to end of follow-up at year two, a mean reduction of -27 ± 16 (-52 to 1)% occurred. Mean temporal choroidal thickness (CT) at baseline was 324 ± 71 (174–404) µm. At year one, a decrease to 249 ± 51 (139–316) µm was observed (-23%; p < 0.0001). At year two, temporal CT further decreased to 220 ± 46 (108–263) µm, resulting in an additional 11% reduction (p = 0.031). Comparing baseline to end of follow-up at year two, a mean reduction of -29 ± 15 (-56 to 2)% occurred.

At baseline, the 8 partner eyes showed a mean SFCT of 355 ± 50 (271–450), a nasal CT of 264 ± 44 (183–310) and a temporal CT of 301 ± 50 (220–384) µm. At year one and two, mean SFCT, nasal and temporal CT remained unchanged (p > 0.13 for all comparisons).

**Correlation of choroidal thickness reduction and anti-VEGF injections**

To test the hypothesis whether the absolute number of anti-VEGF injections correlated with the reduction in choroidal thickness, the Pearson correlation coefficient was calculated. In the first year, a significant strong negative correlation was found (r = -0.79; R² = 0.63; p = .00073; Fig. 2), which was also maintained in the second year (r = -0.69; R² = 0.48; p = .019).

**Choroidal thickness and pachychoroid threshold values**

At baseline, 12 out of the 14 PNV eyes (85.7%) exceeded a pachychoroid threshold of ≥ 350 µm. After anti-VEGF treatment, at year one, this figure dropped to 3 eyes (21.4%; Fig. 3), and at year two, no eye fulfilled the pre-specified threshold.

Considering a pachychoroid threshold of ≥ 300 µm, 13 out of the 14 PNV eyes (92.9%) exceeded this value at baseline. After anti-VEGF treatment, this figure dropped to 4 eyes (28.5%; Fig. 3) at year one, and one eye (9.1%) at year two.

Of the 8 partner eyes, 6 (75%) showed a pachychoroid > 350 µm at baseline, which remained stable with 6 eyes (75%) at year one and 4 out of 6 eyes (66.7%) at year two. The exact same numbers apply for a pachychoroid threshold of > 300 µm.

**Visual acuity**

In the PNV eyes, a mean visual acuity of 0.58 ± 0.39 (0.1–1.3) logMAR at baseline was maintained at year one with 0.54 ± 0.32 (0.1–1.0) logMAR and at year two with 0.68 ± 0.36 (0.1–1.3) logMAR (p = 0.63).
In the partner eyes, the baseline visual acuity of $0.21 \pm 0.24$ ($0.0-0.70$) logMAR remained unchanged at year one with $0.28 \pm 0.37$ ($0.0-1.0$) logMAR and at year two with $0.22 \pm 0.39$ ($0.0-1.0$) logMAR ($p = 0.88$).

**Adverse events**

No serious adverse events (no endophthalmitis, no retinal detachment, and no macular hemorrhage involving the fovea and requiring pneumatic displacement) were observed during the study period.

**Discussion**

In the present study, we sought to test whether choroidal thickness represents a stable, reliable diagnostic criterium to discriminate between pachychoroid and non-pachychoroid neovascular disease, in this case pachychoroid neovasculopathy (PNV).

In accordance with the literature\textsuperscript{2,4,11,21}, we found that the PNV eyes included in our study showed an above-average mean subfoveal choroidal thickness (SFCT) of 400 µm, which is well above the generally established threshold of > 350 µm considered to represent a pachychoroid\textsuperscript{2}. As a new finding, we however describe that this “pachy-choroid” actually disappears with anti-VEGF therapy, and thus does not represent a reliable long-term diagnostic criterium. At two years, after mean 13 anti-VEGF injections, the PNV eyes included in this study showed a mean SFCT reduction by 39 % to a final value of 241 µm, making them, without knowledge of the *status quo ante* at baseline, ineligible for a pachychoroid diagnosis based on above mentioned threshold.

From a clinical perspective, the percentage of eyes presenting with a pachychoroid > 350 µm decreased from 86 % at baseline to 21 % at year one, and 0 % at year two. While it is difficult to give a definite threshold above which choroidal thickness becomes pathological, Cheung et al. state in their major review of the pachychoroid spectrum that “a value exceeding 300 µm will mostly be regarded as pathological”\textsuperscript{2}. This is mainly based on a series of older an newer studies, in which normal sub-foveal choroidal thickness was found to be around 300 µm on average (Margolis and Spaide\textsuperscript{22} 287 µm, Manjunath et al.\textsuperscript{23} 272 µm, Ikuno et al.\textsuperscript{24} 354 µm, Akhtar et al.\textsuperscript{13} 307 µm). Applying this lower threshold of 300 µm to our study, 93 % of eyes fulfilled this criterium at baseline – a figure which however also dropped to 29 % at year one, and 9 % at year two.

Strikingly, not all eyes included in this analysis showed a classic “pachychoroid” of > 350 µm at baseline – even though their “pachychoroid” origin was determined by pre-documented CSC in these eyes. Many factors have been shown to influence SFCT, mainly age\textsuperscript{13} and axial length\textsuperscript{25}. Akhtar et al. for example found a mean subfoveal thickness of $327 \pm 68$ µm for participants aged 12–18 years, as opposed to a mean $262 \pm 72$ µm in participants above 60 years\textsuperscript{13}. In a study by Flores-Moreno et al.\textsuperscript{25}, choroidal thickness decreased by approximately 26 µm per every additional mm of axial length. In this context, our findings further establish anti-VEGF therapy as an important influence on choroidal thickness. In both year one and two, we saw a significant strong correlation of choroidal thinning and the amount of anti-VEGF injections applied. While these data already give a strong hint towards a possible connection, they
are at the same time confirmed by the fact that the untreated partner eyes did not show any significant changes in choroidal thickness, though they largely also suffered from a pachychoroid and pachychoroid-related disease (pachychoroid pigment epitheliopathy, CSC without CNV). This difference between PNV and partner eyes, as well as the follow-up of just below two years should make the influence of aging as a confounding factor rather negligible.

Thinning of the choroid under anti-VEGF has been previously reported for diabetic macular edema, neovascular AMD, retinal vein occlusion and myopic CNV, although some results are conflicting. It is currently unclear which specific changes in the choroid contribute to its thinning during the course of intravitreal anti-VEGF therapy for PNV. Progresive damage to the choriocapillaris, and maybe even Sattler's layer in advanced cases, which PNV certainly signifies, might hint at the pathologically dilated Haller's layer to be the primary location of anti-VEGF action. Within Haller's layer itself, decreases in luminal or stromal, or both departments may be responsible. Recent data analyzing choroidal changes in aging have found that both choroidal stromal and vessel volume decrease in a similar manner, maintaining the choroidal vascularity index (CVI) unaltered. If pachychoroid disorders are to be understood as vascular congestion, and if the therapeutic effect of anti-VEGF should rely in partially alleviating this congestion, it might be intuitive to expect more luminal than stromal changes. Indeed, a recent study analyzing the effect of anti-VEGF on PCV (belonging to the same pathophysiological spectrum as PNV) found that the greatest vertical choroidal vessel diameter significantly decreased with anti-VEGF administration, and increased again prior to the reappearance of macular fluid on OCT. These findings suggest that choroidal thickening in pachychoroid disorders might not only be secondary to dilated, congested vessels, but also due to leakage from the choroidal lumina into the stroma. With this hypothesis, the thinning effects of anti-VEGF on the choroid might be most intuitively explained by a reduction of choroidal leakage from pachyvessels, and thus less stroma swollen by leaked fluid.

Our data directly translate into possible recommendations as how to diagnose PNV. Choroidal thickness should be referenced at baseline, and not used as a diagnostic criterium after commencing anti-VEGF treatment. Moreover, our data also indirectly translate into a better distinction of neovascular pachychoroid disease and age-related macular degeneration (nAMD). It is conceivable that a certain percentage of presumed neovascular AMD, in reality, represents PNV. A relatively high incidence of misdiagnosis might be aggravated by the fact that choroidal thickness does not serve as a good differentiator between both entities in the chronic, anti-VEGF treatment phase. It is these chronically ill eyes, however, in which “AMD non-response” is mostly evaluated – and where PNV can serve as an important differential diagnosis bearing treatment decisions regarding on disease-specific biomarkers. While persistent subretinal fluid, for example, can potentially be tolerated in nAMD, it will inevitably lead to progressive foveal thinning in pachychoroid disease, for which several additional treatment options are under current investigation, including mineralocorticoid receptor antagonists, photodynamic therapy, or non-damaging laser treatments. These options should not be withheld to a patient based on a false diagnosis of presumed nAMD. For these reasons, other biomarkers of pachychoroid disease should be first choice apart from sole choroidal thickness when the eye in question presents with a
history of anti-VEGF treatment. These biomarkers include, e.g., the presence of dilated Haller veins, called pachyvessels, an increased choroidal vascularity index, and choroidal hyperpermeability\textsuperscript{2,41}.

Certain limitations of our study can be found. First of all, our sample size as well as follow-up are limited. Moreover, we cannot give a detailed analysis of choroidal perfusion changes under anti-VEGF therapy as we lack consistent long-term OCT angiography data. Moreover, 14\% of PNV eyes included in this study already presented with SFCT below the 350 µm pachychoroid threshold before commencing anti-VEGF therapy; in these eyes, however, the diagnosis of PNV was confirmed due to a pre-documented history of chronic CSC.

In conclusion, this study demonstrates that choroidal thickness in PNV significantly decreases with anti-VEGF therapy, resembling a “vanishing pachy-choroid”. Thus, choroidal thickness does not represent a valid long-term diagnostic criterium and cannot be used as a safe differentiator from nAMD in these cases. Further analyses of pachychoroid biomarkers beyond sole thickness are warranted, e.g. towards choroidal vascularity index and choroidal stroma-to-vessel volume ratio, which might represent more stable, anti-VEGF independent biomarkers in the diagnosis of neovascular and non-neovascular pachychoroid disease\textsuperscript{42}.

**Abbreviations**

BAF blue autofluorescence

CNV Choroidal Neovascularization

CSC Central serous chorioretinopathy

CSLO confocal scanning laser ophthalmoscopy

CT Choroidal Thickness

EDI Enhanced depth imaging

FA Fluorescein angiography

ICGA Indocyanine green angiography

nAMD Neovascular age-related macular Degeneration

NIR Near-infrared reflectance

OCT Optical coherence tomography

PNV Pachychoroid neovasculopathy

SFCT Sub-foveal choroidal thickness
VEGF Vascular endothelial growth factor

Declarations

Ethics approval and consent to participate

Institutional review board (University Eye Hospital Munich, Ludwig-Maximilians-University Munich) approval was obtained for this retrospective chart review, and the study adhered to the tenets of the Declaration of Helsinki. All patients provided written consent.

Consent for publication

None applicable, as no uniquely identifying information about a single subject are given.

Availability of data and material

Data will be made available upon reasonable request.

Competing interests

No author reports any financial interest relevant to this study.

Benedikt Schworm received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation. Nikolaus Luft received income from honoraria as a lecturer from Alcon Laboratories Inc., NIDEK Co. Ltd and CenterVue SpA. Leonie F Keidel received income from honoraria as a lecturer from Recordati Pharma GmbH. Thomas C Kreutzer received previous speaker fees from Alcon Pharma GmbH. Thomas C Kreutzer received personal consultation fees from Novartis Pharma GmbH and Bayer AG. Thomas C Kreutzer received travel reimbursement from D.O.R.C. (International) B.V. Karsten Kortuem received previous speaker fees and/or travel expenses from Novartis Pharma GmbH, Bayer AG, and Alcon Pharma GmbH. Karsten Kortüm received personal consultation fees from Big Picture Medical. Karsten Kortüm received travel expenses from Pharm-Allergan GmbH and Heidelberg Engineering GmbH. Armin Wolf received previous speaker fees and research funds from Novartis Pharma GmbH, Oertli AG, Bayer AG, Pharm-Allergan GmbH and Alimera Sciences Ophthalmologie GmbH. Tina Rike Herold received income from honoraria as a lecturer from Novartis GmbH, Bayer AG and Pharm-Allergan GmbH. Siegfried Priglinger received previous speaker fees and/or travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharma GmbH and Pharm-Allergan GmbH. Jakob Siedlecki received previous speaker honoraria, personal consultation honoraria and travel expenses from Novartis Pharma GmbH, Bayer AG, Roche AG, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH and Allergan GmbH.

Funding

The authors report no funding.

Authors' contributions
JS, LFK and BS performed multimodal imaging analysis. JS, LFK, BS, NL, TCK, TRH and SGP interpreted the data. JS created the graphs. JS drafted the manuscript. JS, LFK, BS, NL, TCK, TRH and SGP developed the manuscript into its final version.

Acknowledgements

This study was presented at the 118th annual meeting of the German Ophthalmological Society, Berlin 2020.

References

1. Mrejen S, Balaratnasingam C, Kaden TR, et al. Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy. *Ophthalmology*. 2019;126(4):576-588.
2. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. *Eye*. 2019;33(1):14-33.
3. Bonini Filho MA, de Carlo TE, Ferrara D, et al. Association of Choroidal Neovascularization and Central Serous Chorioretinopathy With Optical Coherence Tomography Angiography. *JAMA ophthalmology*. 2015;133(8):899-906.
4. Pang CE, Freund KB. Pachychoroid neovasculopathy. *Retina*. 2015;35(1):1-9.
5. Hwang H, Kim JY, Kim KT, Chae JB, Kim DY. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy? *Retina*. 2019.
6. Siedlecki J, Schworm B, Priglinger SG. The Pachychoroid Disease Spectrum - And the Need for a Uniform Classification System. *Ophthalmology Retina*. 2019;(in press).
7. Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. *Retina*. 2012;32(9):1829-1837.
8. Querques G, Souied EH. Vascularized Drusen: Slowly Progressive Type 1 Neovascularization Mimicking Drusenoid Retinal Pigment Epithelium Elevation. *Retina*. 2015;35(12):2433-2439.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *The New England journal of medicine*. 2006;355(14):1419-1431.
10. Cho HJ, Jung SH, Cho S, Han JO, Park S, Kim JW. Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy. *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics*. 2019;35(3):174-181.
11. Jung BJ, Kim JY, Lee JH, Baek J, Lee K, Lee WK. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. *Scientific Reports*. 2019;9(1):2055.
12. Wei WB, Xu L, Jonas JB, et al. Subfoveal choroidal thickness: the Beijing Eye Study. *Ophthalmology*. 2013;120(1):175-180.
13. Akhtar Z, Rishi P, Srikanth R, Rishi E, Bhende M, Raman R. Choroidal thickness in normal Indian subjects using Swept source optical coherence tomography. *PLoS ONE*. 2018;13(5):e0197457.

14. Gharbiya M, Giustolisi R, Marchiori J, et al. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Afibercept in Treatment-Naive Eyes. *Current eye research*. 2018;43(3):391-396.

15. Mazaraki K, Fassnacht-Riederle H, Blum R, Becker M, Michels S. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. *The British journal of ophthalmology*. 2015;99(10):1341-1344.

16. Schworm B, Luft N, Keidel LF, et al. Vanishing pachy-choroid in pachychoroid neovascularopathy under long-term anti-vascular endothelial growth factor therapy. *Presented at the German Ophthalmological Society Meeting 2020*. 2020.

17. Lau JK, Cheung SW, Collins MJ, Cho P. Repeatability of choroidal thickness measurements with Spectralis OCT images. *BMJ Open Ophthalmol*. 2019;4(1):e000237.

18. Yamashita T, Yamashita T, Shirasawa M, Arimura N, Terasaki H, Sakamoto T. Repeatability and Reproducibility of Subfoveal Choroidal Thickness in Normal Eyes of Japanese Using Different SD-OCT Devices. *Invest Ophthalmol Vis Sci*. 2012;53(3):1102-1107.

19. Freund KB, Korobelnik JF, Devenyi R, et al. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. *Retina*. 2015;35(8):1489-1506.

20. Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovascularopathy and Type 1 neovascular age-related macular degeneration. *Jpn J Ophthalmol*. 2018;62(2):144-150.

21. Kuroda S, Ikuno Y, Yasuno Y, et al. Choroidal thickness in central serous chorioretinopathy. *Retina*. 2013;33(2):302-308.

22. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. *Am J Ophthalmol*. 2009;147(5):811-815.

23. Manjunath V, Taha M, Fujimoto JG, Duker JS. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. *Am J Ophthalmol*. 2010;150(3):325-329.e321.

24. Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y. Choroidal thickness in healthy Japanese subjects. *Invest Ophthalmol Vis Sci*. 2010;51(4):2173-2176.

25. Flores-Moreno I, Lugo F, Duker JS, Ruiz-Moreno JM. The relationship between axial length and choroidal thickness in eyes with high myopia. *Am J Ophthalmol*. 2013;155(2):314-319.e311.

26. Yiu G, Manjunath V, Chiu SJ, Farsiu S, Mahmoud TH. Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. *Am J Ophthalmol*. 2014;158(4):745-751.e742.

27. Kida T, Osuka S, Fukumoto M, et al. Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein
28. Lee JH, Lee SC, Kim SH, et al. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. *Retina*. 2017;37(8):1516-1522.

29. Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. *Clinical ophthalmology (Auckland, NZ)*. 2012;6:837-844.

30. Siedlecki J, Schworm B, Priglinger SG. The Pachychoroid Disease Spectrum-and the Need for a Uniform Classification System. *Ophthalmology Retina*. 2019;3(12):1013-1015.

31. Zhou H, Dai Y, Shi Y, et al. Age-Related Changes in Choroidal Thickness and the Volume of Vessels and Stroma Using Swept-Source OCT and Fully Automated Algorithms. *Ophthalmology Retina*. 2020;4(2):204-215.

32. Matsumoto H, Kishi S, Mukai R, Akiyama H. Remodeling of macular vortex veins in pachychoroid neovascularopathy. *Scientific Reports*. 2019;9(1):14689.

33. Nagai N, Suzuki M, Minami S, et al. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. *Scientific Reports*. 2019;9(1):11389.

34. Thulliez M, Zhang Q, Shi Y, et al. Correlations between Choriocapillaris Flow Deficits around Geographic Atrophy and Enlargement Rates Based on Swept-Source OCT Imaging. *Ophthalmology Retina*. 2019;3(6):478-488.

35. Whitmore SS, Sohn EH, Chirco KR, et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. *Progress in retinal and eye research*. 2015;45:1-29.

36. Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. *Ophthalmology*. 2018.

37. Breukink MB, Dingemans AJ, den Hollander Al, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. *Clinical ophthalmology (Auckland, NZ)*. 2017;11:39-46.

38. Bousquet E, Beydoun T, Rothschild PR, et al. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. *Retina*. 2015;35(12):2505-2515.

39. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. *Retina*. 2013;33(10):2096-2102.

40. van Dijk EHC, Fauser S, Breukink MB, et al. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. *Ophthalmology*. 2018;125(10):1547-1555.
41. Agrawal R, Chhablani J, Tan KA, Shah S, Sarvaiya C, Banker A. CHOROIDAL VASCULARITY INDEX IN CENTRAL SEROUS CHORIORETINOPATHY. *Retina*. 2016;36(9):1646-1651.

42. Zhou H, Dai Y, Lyu C, et al. Age-related changes in choroidal thickness and the volume of vessels and stroma using swept source OCT and fully automated algorithms. *Ophthalmology Retina*. 2019.

**Tables**

**Table 1 Baseline demographic data**
Table 2 Choroidal thickness in PNV and partner eyes during follow-up

| No. of eyes (n) | 22 |
|----------------|----|
| PNV eyes       | 14 |
| Right / Left   | 8 / 6 |
| Partner eyes   | 8 |
| Right / Left   | 3 / 5 |

| No. of patients (n) | 11 |
| Gender (m/f)        | 7/4 |
| Mean age (years)    | 64.2 ± 4.0 (range 60 – 72) |

| Mean follow-up (y) | 1.8 ± 0.4 (1.00 – 2.00) |
|--------------------|-------------------------|
| Year 1             | 22 (100 %)              |
| Year 2             | 17 (77.2 %)              |

Pachychoroid disease stage

| PNV eyes (n = 14) |  |
|-------------------|---|
| 1 (PPE)           | 0 |
| 2 (CSC)           | 0 |
| 3 (PNV)           | 14 (100 %) |
| 4 (PAT1)          | 0 |

| Partner eyes (n = 8) |  |
|----------------------|---|
| 1 (PPE)              | 4 (50 %) |
| 2 (CSC)              | 1 (12.5 %) |
| 3 (PNV)              | 0 |
| 4 (PAT1)             | 0 |

Macular morphology

| PNV eyes |  |
|----------|---|
| Subretinal fluid | 14 (100 %) |
| Intraretinal fluid | 0 |
| Flat, irregular PED | 14 (100 %) |
| CNV | 14 (100 %) |

| Partner eyes |  |
|--------------|---|
| Subretinal fluid | 0 |
| Intraretinal fluid | 0 |
| Flat, irregular PED | 0 |
| CNV | 0 |

Mean Ranibizumab injections

| PNV eyes |  |
|----------|---|
| Year 1 | 7.0 ± 2.9 (2 – 11) |
| Year 2 | 6.5 ± 3.1 (1 – 10) |

| Partner Eyes |  |
|--------------|---|
| Year 1 | 0 |
| Year 2 | 0 |
Figures

|       | Baseline choroidal thickness (µm) | Year 1 choroidal thickness (µm) | % reduction | P     | Year 2 choroidal thickness (µm) | % reduction | P   |
|-------|----------------------------------|---------------------------------|-------------|-------|---------------------------------|-------------|-----|
| Eyes with PNV |                                   |                                 |             |       |                                 |             |     |
| subfoveal | 400.3 ± 57.9 (269 – 485)          | 295.3 ± 52.8 (210 – 393)        | -0.25 ± 0.14 | .00003 | 241.4 ± 52.4 (162 – 327)        | -0.20 ± 0.13 | .0003 |
| nasal    | 311.9 ± 42.1 (243 – 396)          | 249.0 ± 47.2 (180 – 332)        | -0.19 ± 0.17 | .0018 | 221.5 ± 40.2 (178 – 315)        | -0.12 ± 0.16 | .017 |
| temporal | 323.9 ± 71.1 (174 – 404)          | 248.6 ± 50.8 (139 – 316)        | -0.23 ± 0.09 | <0.0001 | 219.5 ± 45.8 (108 – 263)        | -0.11 ± 0.15 | .031 |

Partner eyes

|       | Baseline choroidal thickness (µm) | Year 1 choroidal thickness (µm) | % reduction | P | Year 2 choroidal thickness (µm) | % reduction | P |
|-------|----------------------------------|---------------------------------|-------------|---|---------------------------------|-------------|---|
| subfoveal | 354.5 ± 50.3 (271 – 425)          | 347.5 ± 54.1 (262 – 403)        | -0.02 ± 0.04 | .19 | 350.5 ± 74.7 (252 – 449)        | -0.01 ± 0.10 | .48 |
| nasal    | 264.1 ± 43.8 (183 – 310)          | 257.1 ± 55.7 (158 – 324)        | -0.03 ± 0.13 | .57 | 266.5 ± 55.1 (183 – 324)        | 0.03 ± 0.12 | .50 |
| temporal | 301.4 ± 50.0 (220 – 384)          | 308.6 ± 56.7 (195 – 364)        | 0.02 ± 0.11 | .67 | 262.3 ± 33.8 (200 – 296)        | -0.07 ± 0.09 | .13 |

correlation with number of injections:

- PNV Eyes: $r = -0.79$; $R^2 = 0.63$; $p = .00073$
- Partner Eyes: $r = -0.69$; $R^2 = 0.48$; $p = .019$

Figure 1

Changes in choroidal thickness during follow-up. In PNV eyes, choroidal thickness decreased in all subfields evaluated (subfoveal, nasal, temporal). Mean SFCT at baseline of 400 ± 58 (269 – 485) µm showed a mean reduction of -39 ± 10 (-26 to -56) % during follow-up to a final 241 ± 52 (162 – 327) µm.
at year two. Mean nasal choroidal thickness (CT) at baseline of 312 ± 42 (243 – 368) µm showed a mean reduction of -27 ± 16 (-52 to 1) % to a final 222 ± 40 (178 – 315) µm at year two. Mean temporal choroidal thickness (CT) at baseline of 324 ± 71 (174 – 404) µm showed a mean reduction of -29 ± 15 (-56 to 2) % to a final 220 ± 46 (108 – 263) µm at year two. At baseline, the 8 partner eyes showed a mean SFCT of 355 ± 50 (271 – 450), a nasal CT of 264 ± 44 (183 – 310) and a temporal CT of 301 ± 50 (220 – 384) µm. At year one and two, mean SFCT, nasal and temporal CT remained unchanged (p>0.13 for all comparisons).

**Graph:**

- $r = -0.79$
- $R^2 = 0.63$
- $p = 0.00073$
Figure 2

Correlation of subfoveal choroidal thinning and amount of anti-VEGF injections in the first year. A significant strong negative correlation was found ($r = -0.79$; $R^2 = 0.63$; $p = .00073$; Fig. 1). In year two, this correlation was maintained ($r = -0.69$; $R^2 = 0.48$; $p = .019$).

![Graph showing correlation](image)

Figure 3

Percentage of PNV eyes fulfilling pachychoroid disease diagnostic thresholds at baseline, year one and two. At baseline, 12 out of the 14 PNV eyes (85.7 %) exceeded a pachychoroid threshold of $\geq 350 \mu m$. After anti-VEGF treatment, at year one, this figure dropped to 3 eyes (21.4 %), and at year two, no eye fulfilled the threshold. Considering a pachychoroid threshold of $\geq 300 \mu m$, 13 out of the 14 PNV eyes (92.9 %) exceeded this value at baseline. After anti-VEGF treatment, this figure dropped to 4 eyes (28.5 %) at year one, and one eye (9.1 %) at year two.